Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …

Aims: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been
demonstrated in patients with advanced non‐small‐cell lung cancer (NSCLC). Tarceva lung …

Introduction: Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in
Japanese patients with non–small-cell lung cancer (NSCLC) receiving erlotinib. To …

19000 Background: Erlotinib significantly improved survival and quality of life while delaying
symptom progression compared with placebo in patients (pts) with relapsed NSCLC …

Background A retrospective analysis of clinical data were conducted reviewing patients who
were given erlotinib at Peking Union Medical College (PUMC) Hospital from May 2005 to …

Introduction The purpose of this study was to describe treatment use patterns and outcomes
with single-agent erlotinib among patients with advanced Non–Small-cell lung cancer …

Background: Erlotinib is a standard of treatment for metastatic non-small-cell lung cancer
after failure of initial therapy. Patient selection based on clinical factors is under discussion …

chemotherapy in terms of PFS, main endpoint of the trial, with 9.7 versus 5.2 months,
respectively (HR 0.37, 95% CI 0.25-0.54). ORRs were 58% and 15%, respectively. OS data …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …